[<sup>99m</sup>Tc]Tc-iFAP/SPECT Tumor Stroma Imaging: Acquisition and Analysis of Clinical Images in Six Different Cancer Entities
Fibroblast activation protein (FAP) is highly expressed on the cancer-associated fibroblasts (CAF) of the tumor stroma. Recently, we reported the preclinical evaluation and clinical biokinetics of a novel <sup>99m</sup>Tc-labeled FAP inhibitor radioligand ([<sup>99m</sup>Tc]T...
Saved in:
Main Authors: | , , , , , , , , |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Fibroblast activation protein (FAP) is highly expressed on the cancer-associated fibroblasts (CAF) of the tumor stroma. Recently, we reported the preclinical evaluation and clinical biokinetics of a novel <sup>99m</sup>Tc-labeled FAP inhibitor radioligand ([<sup>99m</sup>Tc]Tc-iFAP). This research aimed to evaluate [<sup>99m</sup>Tc]Tc-iFAP for the tumor stroma imaging of six different cancerous entities and analyze them from the perspective of stromal heterogeneity. [<sup>99m</sup>Tc]Tc-iFAP was prepared from freeze-dried kits with a radiochemical purity of 98 ± 1%. The study included thirty-two patients diagnosed with glioma (<i>n</i> = 5); adrenal cortex neuroendocrine tumor (<i>n</i> = 1); and breast (<i>n</i> = 21), lung (<i>n</i> = 2), colorectal (<i>n</i> = 1) and cervical (<i>n</i> = 3) cancer. Patients with glioma had been evaluated with a previous cranial MRI scan and the rest of the patients had been involved in a [<sup>18</sup>F]FDG PET/CT study. All oncological diagnoses were corroborated histopathologically. The patients underwent SPECT/CT brain imaging (glioma) or thoracoabdominal imaging 1 h after [<sup>99m</sup>Tc]Tc-iFAP administration (i.v., 735 ± 63 MBq). The total lesions (<i>n</i> = 111) were divided into three categories: primary tumors (PT), lymph node metastases (LNm), and distant metastases (Dm). [<sup>99m</sup>Tc]Tc-iFAP brain imaging was positive in four high-grade WHO III-IV gliomas and negative in one treatment-naive low-grade glioma. Both [<sup>99m</sup>Tc]Tc-iFAP and [<sup>18</sup>F]FDG detected 26 (100%) PT, although the number of positive LNm and Dm was significantly higher with [<sup>18</sup>F]FDG [82 (96%)], in comparison to [<sup>99m</sup>Tc]Tc-iFAP imaging (35 (41%)). Peritoneal carcinomatosis lesions in a patient with recurrent colorectal cancer were only visualized with [<sup>99m</sup>Tc]Tc-iFAP. In patients with breast cancer, a significant positive correlation was demonstrated among [<sup>99m</sup>Tc]Tc-iFAP uptake values (Bq/cm<sup>3</sup>) of PT and the molecular subtype, being higher for subtypes HER2+ and Luminal B HER2-enriched. Four different CAF subpopulations have previously been described for LNm of breast cancer (from CAF-S1 to CAF-S4). The only subpopulation that expresses FAP is CAF-S1, which is preferentially detected in aggressive subtypes (HER2 and triple-negative), confirming that FAP+ is a marker for poor disease prognosis. The results of this pilot clinical research show that [<sup>99m</sup>Tc]Tc-iFAP SPECT imaging is a promising tool in the prognostic assessment of some solid tumors, particularly breast cancer. |
---|---|
Item Description: | 10.3390/ph15060729 1424-8247 |